EirGenix showcases biosimilars, CDMO strategy
Analysis based on 6 articles · First reported Jun 30, 2026 · Last updated Jun 30, 2026
The event is expected to have a positive impact on the pharmaceutical and biotechnology markets, particularly for companies involved in biosimilar development and CDMO services. EirGenix's dual-track strategy positions it to capitalize on the upcoming patent cliff for biologics and the increasing demand for outsourced manufacturing, potentially leading to increased competition and innovation in the breast cancer drug market.
At BIO 2026, EirGenix presented its comprehensive HER2-positive breast cancer biosimilar portfolio and its integrated contract development and manufacturing organization (CDMO) service platform. The company is actively pursuing U.S. market opportunities and global partnerships. This dual-track strategy aims to capture high-potential oncology opportunities and accelerate global commercialization for partners. The global breast cancer drug market is projected to grow significantly, driven by a large patient population and rising treatment demand. EirGenix is strategically prioritizing HER2-positive breast cancer within its biosimilar portfolio, including trastuzumab and pertuzumab, and advancing next-generation ADC biosimilars. The company is also exploring combination therapy strategies. The biopharmaceutical industry is facing a major patent cliff, creating vast opportunities for biosimilar developers. Global regulatory frameworks, including those from the United States — Food and Drug Administration and the European Union — European Medicines Agency, are harmonizing, streamlining biosimilar approval. EirGenix's CDMO services are a second core pillar, addressing the growing demand for outsourcing in the pharmaceutical industry due to global supply chain restructuring and the rise of biotech startups. EirGenix operates a fully integrated, commercially scaled platform covering the entire product lifecycle, from cell line engineering to GMP manufacturing, for monoclonal antibodies, bispecific antibodies, and other complex biologics. The company aims to expand its global footprint and leverage its platform to support clients, accelerating development timelines and improving commercialization efficiency.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard